{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T06:13:14Z","timestamp":1783750394537,"version":"3.55.0"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40262-026-01657-x","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:22:49Z","timestamp":1780474969000},"page":"995-1011","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Collecting Metabolite Pharmacokinetics in Drug\u2013Drug Interaction Studies: A Review of Industry Practices and Data Utilization"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9339-6811","authenticated-orcid":false,"given":"Tatyana","family":"Dubich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5754-6165","authenticated-orcid":false,"given":"Thijs","family":"van Iersel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5935-4220","authenticated-orcid":false,"given":"Kamelia","family":"Mirdamadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4334-2073","authenticated-orcid":false,"given":"Ewoud-Jan","family":"van Hoogdalem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"1657_CR1","unstructured":"(ICH) IC for H of TR for P for HU. M12 Guideline on drug interaction studies. 2024."},{"key":"1657_CR2","unstructured":"Development TC for the S of D. Rising protocol design complexity is driving rapid growth in clinical trial data volume. 2021. Report."},{"issue":"1","key":"1657_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06973-8","volume":"23","author":"H Gardner","year":"2022","unstructured":"Gardner H, Elfeky A, Pickles D, Dawson A, Gillies K, Warwick V, et al. A good use of time? Providing evidence for how effort is invested in primary and secondary outcome data collection in trials. Trials. 2022;23(1):1047. https:\/\/doi.org\/10.1186\/s13063-022-06973-8.","journal-title":"Trials"},{"issue":"1","key":"1657_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-019-1476-5","volume":"18","author":"N Naidoo","year":"2020","unstructured":"Naidoo N, Nguyen VT, Ravaud P, Young B, Amiel P, Schant\u00e9 D, et al. The research burden of randomized controlled trial participation: a systematic thematic synthesis of qualitative evidence. BMC Med. 2020;18(1):6. https:\/\/doi.org\/10.1186\/s12916-019-1476-5.","journal-title":"BMC Med"},{"issue":"1","key":"1657_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/2168479017713039","volume":"52","author":"KA Getz","year":"2018","unstructured":"Getz KA, Campo RA. New benchmarks characterizing growth in protocol design complexity. Ther Innov Regul Sci. 2018;52(1):22\u20138. https:\/\/doi.org\/10.1177\/2168479017713039.","journal-title":"Ther Innov Regul Sci"},{"issue":"2","key":"1657_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/MJT.0b013e31826fc4aa","volume":"22","author":"KA Getz","year":"2015","unstructured":"Getz KA, Stergiopoulos S, Marlborough M, Whitehill J, Curran M, Kaitin KI. Quantifying the magnitude and cost of collecting extraneous protocol data. Am J Ther. 2015;22(2):117\u201324. https:\/\/doi.org\/10.1097\/MJT.0b013e31826fc4aa.","journal-title":"Am J Ther"},{"issue":"5","key":"1657_CR7","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.3390\/ijerph110505069","volume":"11","author":"K Getz","year":"2014","unstructured":"Getz K. Improving protocol design feasibility to drive drug development economics and performance. Int J Environ Res Public Health. 2014;11(5):5069\u201380. https:\/\/doi.org\/10.3390\/ijerph110505069.","journal-title":"Int J Environ Res Public Health"},{"issue":"5","key":"1657_CR8","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/MJT.0b013e31816b9027","volume":"15","author":"KA Getz","year":"2008","unstructured":"Getz KA, Wenger J, Campo RA, Seguine ES, Kaitin KI. Assessing the impact of protocol design changes on clinical trial performance. Am J Ther. 2008;15(5):450\u20137. https:\/\/doi.org\/10.1097\/MJT.0b013e31816b9027.","journal-title":"Am J Ther"},{"key":"1657_CR9","unstructured":"Administration USF& D. FDA\u2019s Examples of Drugs that Interact with CYP Enzymes and Transporter Systems [Internet]. 2025. Available from: https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems. Accessed 13 Aug 2025."},{"issue":"4","key":"1657_CR10","doi-asserted-by":"publisher","first-page":"e1252","DOI":"10.1002\/prp2.1252","volume":"12","author":"J Chen","year":"2024","unstructured":"Chen J, Li J, Wu J, Song Y, Li L, Zhang J, et al. An open-label study to explore the optimal design of CYP3A drug-drug interaction clinical trials in healthy Chinese people. Pharmacol Res Perspect. 2024;12(4):e1252\u2013e1252. https:\/\/doi.org\/10.1002\/prp2.1252.","journal-title":"Pharmacol Res Perspect"},{"issue":"3","key":"1657_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/clpt.2014.83","volume":"96","author":"M Bosilkovska","year":"2014","unstructured":"Bosilkovska M, Samer CF, D\u00e9glon J, Rebsamen M, Staub C, Dayer P, et al. Geneva cocktail for cytochrome P450 and P-glycoprotein activity assessment using dried blood spots. Clin Pharmacol Ther. 2014;96(3):349\u201359. https:\/\/doi.org\/10.1038\/clpt.2014.83.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1657_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s002280050420","volume":"54","author":"JT Backman","year":"1998","unstructured":"Backman JT, Kivist\u00f6 KT, Olkkola KT, Neuvonen PJ. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol. 1998;54(1):53\u20138. https:\/\/doi.org\/10.1007\/s002280050420.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1657_CR13","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00280-020-04180-3","volume":"87","author":"FK Hurtado","year":"2021","unstructured":"Hurtado FK, de Braud F, De Castro Carpe\u00f1o J, de Miguel Luken MJ, Wang D, Scott J, et al. Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK\u2009+\u2009advanced tumors. Cancer Chemother Pharmacol. 2021;87(4):475\u201386. https:\/\/doi.org\/10.1007\/s00280-020-04180-3.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"1657_CR14","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s40262-022-01144-z","volume":"61","author":"A Topletz-Erickson","year":"2022","unstructured":"Topletz-Erickson A, Lee A, Rustia EL, Sun H, Mayor JG, Abdulrasool LI, et al. Evaluation of safety and clinically relevant drug-drug interactions with Tucatinib in healthy volunteer\ufeffs. Clin Pharmacokinet. 2022;61(10):1417\u201326. https:\/\/doi.org\/10.1007\/s40262-022-01144-z.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1657_CR15","doi-asserted-by":"publisher","first-page":"e01143","DOI":"10.1002\/prp2.1143","volume":"11","author":"B Berger","year":"2023","unstructured":"Berger B, Kaufmann P, Berse M, Treiber A, Grignaschi N, Dingemanse J. Effect of Nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450\u00a0probe substrates in vitro and in vivo using a cocktail approach in healthy subjects. Pharmacol Res Perspect. 2023;11(5):e01143\u2013e01143. https:\/\/doi.org\/10.1002\/prp2.1143.","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"1657_CR16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/cpt.1599","volume":"107","author":"NS Jones","year":"2020","unstructured":"Jones NS, Yoshida K, Salphati L, Kenny JR, Durk MR, Chinn LW. Complex DDI by Fenebrutinib and the use of transporter endogenous biomarkers to elucidate the mechanism of DDI. Clin Pharmacol Ther. 2020;107(1):269\u201377. https:\/\/doi.org\/10.1002\/cpt.1599.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1657_CR17","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/psp4.12939","volume":"12","author":"DJ Mulford","year":"2023","unstructured":"Mulford DJ, Ramsden D, Zhang L, Michon I, Leifke E, Smith N, et al. Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for Vonoprazan using PBPK modeling and clinical data to inform labeling. CPT Pharmacomet Syst Pharmacol. 2023;12(4):532\u201344. https:\/\/doi.org\/10.1002\/psp4.12939.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"3","key":"1657_CR18","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1124\/jpet.123.001681","volume":"387","author":"JT Nguyen","year":"2023","unstructured":"Nguyen JT, Tian DD, Tanna RS, Arian CM, Calamia JC, Rettie AE, et al. An integrative approach to elucidate mechanisms underlying the pharmacokinetic Goldenseal-Midazolam interaction: Application of in vitro assays and physiologically based pharmacokinetic models to understand clinical observations. J Pharmacol Exp Ther. 2023;387(3):252\u201364. https:\/\/doi.org\/10.1124\/jpet.123.001681.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1657_CR19","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00280-023-04554-3","volume":"92","author":"M N\u00e5g\u00e5rd","year":"2023","unstructured":"N\u00e5g\u00e5rd M, Ah-See ML, Strauss J, Wise-Draper T, Safran HP, Nadeau L, et al. Phase I study to assess the effect of Adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2023;92(3):193\u2013203. https:\/\/doi.org\/10.1007\/s00280-023-04554-3.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"1657_CR20","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/cts.13525","volume":"16","author":"M Anliker-Ort","year":"2023","unstructured":"Anliker-Ort M, Dingemanse J, Delahaye S, Jan\u016f L, van den Anker J, Berger B, et al. Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT-1014-6470 in vitro and in vivo. Clin Transl Sci. 2023;16(7):1220\u201331. https:\/\/doi.org\/10.1111\/cts.13525.","journal-title":"Clin Transl Sci"},{"key":"1657_CR21","unstructured":"Oncology L. FDA Drug Approval Package: RETEVMO; Application Number: 213246. 2020. Report."},{"key":"1657_CR22","unstructured":"Sun Pharmaceutical Industries Inc. Drug Approval Package: LEQSELVI, 8 MG TABLETS; Application Number: 217900. 2024. Report."},{"key":"1657_CR23","unstructured":"S.p.A. I. Drug Approval Package: DUVYZAT; Application Number: 217865. 2024. Report."},{"key":"1657_CR24","unstructured":"Melinta Therapeutics Inc. FDA Drug Approval Package Baxdela (delafloxacin); Application No.: 208610 and 208611. 2017. Report."},{"issue":"3","key":"1657_CR25","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s13318-020-00607-7","volume":"45","author":"R Shumaker","year":"2020","unstructured":"Shumaker R, Ren M, Aluri J, Dutcus CE, Rance C, He C. An open-label Phase 1 study to determine the effect of Lenvatinib on the pharmacokinetics of Midazolam, a CYP3A4 substrate, in patients with advanced solid tumors. Eur J Drug Metab Pharmacokinet. 2020;45(3):373\u201383. https:\/\/doi.org\/10.1007\/s13318-020-00607-7.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"12","key":"1657_CR26","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/jcph.1672","volume":"60","author":"HT Bunn","year":"2020","unstructured":"Bunn HT, Rosenthal E, Mathur P, McLaughlin M, Proschan M, Vijan A, et al. The effect of GS-548351 on the pharmacokinetics of Midazolam following multiple doses of ANS-6637 in healthy adults. J Clin Pharmacol. 2020;60(12):1598\u2013605. https:\/\/doi.org\/10.1002\/jcph.1672.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1657_CR27","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s13318-019-00590-8","volume":"45","author":"PN Sidharta","year":"2020","unstructured":"Sidharta PN, Dingemanse J. Effect of multiple-dose Aprocitentan administration on the pharmacokinetics of Midazolam in healthy male subjects. Eur J Drug Metab Pharmacokinet. 2020;45(2):227\u201334. https:\/\/doi.org\/10.1007\/s13318-019-00590-8.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"6","key":"1657_CR28","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.clinthera.2017.04.009","volume":"39","author":"SK Paulson","year":"2017","unstructured":"Paulson SK, Wood-Horrall RN, Hoover R, Quintas M, Lawrence LE, Cammarata SK. The pharmacokinetics of the CYP3A substrate Midazolam after steady-state dosing of Delafloxacin. Clin Ther. 2017;39(6):1182\u201390. https:\/\/doi.org\/10.1016\/j.clinthera.2017.04.009.","journal-title":"Clin Ther"},{"issue":"6","key":"1657_CR29","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s13318-023-00856-2","volume":"48","author":"R Marino","year":"2023","unstructured":"Marino R, Dube L, Ogier J, Le Quan Sang KH. The pharmacokinetic profile of Palovarotene: An open-label Phase I trial investigating the effect of food and potential for drug-drug interaction in healthy participants. Eur J Drug Metab Pharmacokinet. 2023;48(6):691\u2013707. https:\/\/doi.org\/10.1007\/s13318-023-00856-2.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1657_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155550","volume":"143","author":"S Bianzano","year":"2023","unstructured":"Bianzano S, Henrich A, Herich L, Kalsch B, Sarubbi D, Seitz F, et al. Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight\/obesity: Data from two Phase I, randomised, placebo-controlled studies. Metabolism. 2023;143:155550. https:\/\/doi.org\/10.1016\/j.metabol.2023.155550.","journal-title":"Metabolism"},{"issue":"3","key":"1657_CR31","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40263-019-00697-1","volume":"34","author":"M Richard","year":"2020","unstructured":"Richard M, Kaufmann P, Ort M, Kornberger R, Dingemanse J. Multiple-ascending dose study in healthy subjects to assess the pharmacokinetics, tolerability, and CYP3A4 interaction potential of the T-Type calcium channel blocker ACT-709478, a potential new antiepileptic drug. CNS Drugs. 2020;34(3):311\u201323. https:\/\/doi.org\/10.1007\/s40263-019-00697-1.","journal-title":"CNS Drugs"},{"issue":"3","key":"1657_CR32","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/bcp.13467","volume":"84","author":"TB Stage","year":"2018","unstructured":"Stage TB, Graff M, Wong S, Rasmussen LL, Nielsen F, Potteg\u00e5rd A, et al. Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro. Br J Clin Pharmacol. 2018;84(3):510\u20139. https:\/\/doi.org\/10.1111\/bcp.13467.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"1657_CR33","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1002\/cpdd.1164","volume":"11","author":"J Vandenbossche","year":"2022","unstructured":"Vandenbossche J, Yogaratnam J, Hillewaert V, Rasschaert F, Talloen W, Biewenga J, et al. Drug-drug interactions with the Hepatitis B Virus capsid assembly modulator JNJ-56136379 (Bersacapavir). Clin Pharmacol Drug Dev. 2022;11(12):1419\u201329. https:\/\/doi.org\/10.1002\/cpdd.1164.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"1657_CR34","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1002\/cpt.2419","volume":"110","author":"D Vassiliou","year":"2021","unstructured":"Vassiliou D, Sardh E, Harper P, Simon AR, Clausen VA, Najafian N, et al. A drug\u2010drug interaction study evaluating the effect of Givosiran, a small interfering ribonucleic acid, on Cytochrome P450 activity in the liver. Clin Pharmacol Ther. 2021;110(5):1250\u201360. https:\/\/doi.org\/10.1002\/cpt.2419.","journal-title":"Clin Pharmacol Ther"},{"key":"1657_CR35","unstructured":"Novo Nordisk A\/S CRA and D. An Open-label, Single-Sequence, Cross-over Trial Investigating the Influence of NNC9204-1177 on Pharmacokinetics of Index Substrates for Cytochrome P450 Enzymes. Clinical Trial Report Synopsis. 2020. Report."},{"issue":"8","key":"1657_CR36","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/cpdd.961","volume":"10","author":"X Dai","year":"2021","unstructured":"Dai X, Karol MD, Hitron M, Hard ML, Goulet MT, McLaughlin CF, et al. Napabucasin drug\u2010drug interaction potential, safety, tolerability, and pharmacokinetics following oral dosing in healthy adult volunteers. Clin Pharmacol Drug Dev. 2021;10(8):824\u201339. https:\/\/doi.org\/10.1002\/cpdd.961.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"1657_CR37","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/cts.12557","volume":"11","author":"Y Ishii","year":"2018","unstructured":"Ishii Y, Ito Y, Matsuki S, Sanpei K, Ogawa O, Takeda K, et al. Clinical drug\u2013drug interaction potential of BFE1224, prodrug of antifungal Ravuconazole, using two types of cocktails in healthy subjects. Clin Transl Sci. 2018;11(5):477\u201386. https:\/\/doi.org\/10.1111\/cts.12557.","journal-title":"Clin Transl Sci"},{"issue":"6","key":"1657_CR38","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/cpt.2141","volume":"109","author":"F Bachmann","year":"2021","unstructured":"Bachmann F, Duthaler U, Meyer Zu Schwabedissen HE, Puchkov M, Huwyler J, Haschke M, et al. Metamizole is a moderate cytochrome P450 inducer via the constitutive androstane receptor and a weak inhibitor of CYP1A2. Clin Pharmacol Ther. 2021;109(6):1505\u201316. https:\/\/doi.org\/10.1002\/cpt.2141.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"1657_CR39","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.1111\/bcp.14874","volume":"87","author":"F Bachmann","year":"2021","unstructured":"Bachmann F, Duthaler U, Kr\u00e4henb\u00fchl S. Effect of deglucuronidation on the results of the Basel phenotyping cocktail. Br J Clin Pharmacol. 2021;87(12):4608\u201318. https:\/\/doi.org\/10.1111\/bcp.14874.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1657_CR40","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.clpt.2005.09.014","volume":"79","author":"DJ Greenblatt","year":"2006","unstructured":"Greenblatt DJ, von Moltke LL, Perloff ES, Luo Y, Harmatz JS, Zinny MA. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. Clin Pharmacol Ther. 2006;79(1):125\u201333. https:\/\/doi.org\/10.1016\/j.clpt.2005.09.014.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1657_CR41","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1002\/cpt.3610","volume":"117","author":"L Aurinsalo","year":"2025","unstructured":"Aurinsalo L, Lapatto-Reiniluoto O, Kurkela M, Neuvonen M, Kiiski JI, Niemi M, et al. A phenotyping tool for seven cytochrome P450 enzymes and two transporters: application to examine the effects of clopidogrel and gemfibrozil. Clin Pharmacol Ther. 2025;117(6):1732\u201342. https:\/\/doi.org\/10.1002\/cpt.3610.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1657_CR42","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/cpdd.1408","volume":"13","author":"M de Vries","year":"2024","unstructured":"de Vries M, Bonsmann S, Pausch J, Sumner M, Birkmann A, Zimmermann H, et al. Evaluation of the clinical drug\u2010drug interaction potential of pritelivir on transporters and CYP450 enzymes using a cocktail approach. Clin Pharmacol Drug Dev. 2024;13(7):755\u201369. https:\/\/doi.org\/10.1002\/cpdd.1408.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1657_CR43","unstructured":"GlaxoSmithKline. Clinical Study Report Synopsis for Study No: EMI112684. Validation Study of Simultaneous Administration of Multiple Cytochrome P450\/Transporter Probes for Drug Interaction Evaluation in Healthy Adult Subjects. 2011. Report."},{"issue":"2","key":"1657_CR44","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1365-2125.2012.04194.x","volume":"74","author":"S Piscitelli","year":"2012","unstructured":"Piscitelli S, Kim J, Gould E, Lou Y, White S, de Serres M, et al. Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor. Br J Clin Pharmacol. 2012;74(2):336\u201345. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04194.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1657_CR45","unstructured":"Squibb BM. Prescribing Information. IDHIFA\u00ae (enasidenib). Reference ID: 5513378. 2025. Report."},{"issue":"1","key":"1657_CR46","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/s0928-0987(01)00144-0","volume":"14","author":"JM Hutzler","year":"2001","unstructured":"Hutzler JM, Frye RF, Korzekwa KR, Branch RA, Huang SM, Tracy TS. Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone. Eur J Pharm Sci. 2001;14(1):47\u201352. https:\/\/doi.org\/10.1016\/s0928-0987(01)00144-0.","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"1657_CR47","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1067\/mcp.2002.121788","volume":"71","author":"M Christensen","year":"2002","unstructured":"Christensen M, Tybring G, Mihara K, Yasui-Furokori N, Carrillo JA, Ramos SI, et al. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther. 2002;71(3):141\u201352. https:\/\/doi.org\/10.1067\/mcp.2002.121788.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1657_CR48","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jphs.2019.03.001","volume":"139","author":"C Kamiya","year":"2019","unstructured":"Kamiya C, Inui N, Hakamata A, Miyakawa S, Tanaka S, Uchida S, et al. Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype. J Pharmacol Sci. 2019;139(4):361\u20136. https:\/\/doi.org\/10.1016\/j.jphs.2019.03.001.","journal-title":"J Pharmacol Sci"},{"issue":"6","key":"1657_CR49","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/jcph.1789","volume":"61","author":"M Mahmoudi","year":"2021","unstructured":"Mahmoudi M, Foerster KI, Burhenne J, Weiss J, Mikus G, Haefeli WE. Application of microdosed intravenous omeprazole to determine hepatic CYP2C19 activity. J Clin Pharmacol. 2021;61(6):789\u201398. https:\/\/doi.org\/10.1002\/jcph.1789.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1657_CR50","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/j.1365-2125.2003.02047.x","volume":"57","author":"N Yasui-Furukori","year":"2004","unstructured":"Yasui-Furukori N, Takahata T, Nakagami T, Yoshiya G, Inoue Y, Kaneko S, et al. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol. 2004;57(4):487\u201394. https:\/\/doi.org\/10.1111\/j.1365-2125.2003.02047.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1657_CR51","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/clpt.2011.249","volume":"91","author":"V Michaud","year":"2012","unstructured":"Michaud V, Ogburn E, Thong N, Aregbe AO, Quigg TC, Flockhart DA, et al. Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers. Clin Pharmacol Ther. 2012;91(3):475\u201382. https:\/\/doi.org\/10.1038\/clpt.2011.249.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1657_CR52","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1177\/0091270009333016","volume":"49","author":"BL Chen","year":"2009","unstructured":"Chen BL, Chen Y, Tu JH, Li YL, Zhang W, Li Q, et al. Clopidogrel inhibits CYP2C19-dependent hydroxylation of Omeprazole related to CYP2C19 genetic polymorphisms. J Clin Pharmacol. 2009;49(5):574\u201381. https:\/\/doi.org\/10.1177\/0091270009333016.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"1657_CR53","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/cpdd.956","volume":"10","author":"J Desrivot","year":"2021","unstructured":"Desrivot J, Van Kaem T, Allamassey L, Helmer E. Effect of GLPG1205, a GPR84 modulator, on CYP2C9, CYP2C19, and CYP1A2 enzymes: In vitro and phase 1 studies. Clin Pharmacol Drug Dev. 2021;10(9):1007\u201317. https:\/\/doi.org\/10.1002\/cpdd.956.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"1657_CR54","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/jcph.1496","volume":"60","author":"MEF Mohamed","year":"2020","unstructured":"Mohamed MEF, Feng T, Enejosa JV, Fisniku O, Othman AA. Effects of Upadacitinib coadministration on the pharmacokinetics of sensitive cytochrome P450 probe substrates: A study with the modified Cooperstown 5+1 cocktail. J Clin Pharmacol. 2020;60(1):86\u201395. https:\/\/doi.org\/10.1002\/jcph.1496.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1657_CR55","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1046\/j.1365-2125.2002.01366.x","volume":"53","author":"JY Cho","year":"2002","unstructured":"Cho JY, Yu KS, Jang IJ, Yang BH, Shin SG, Yim DS. Omeprazole hydroxylation is inhibited by a single dose of Moclobemide in homozygotic EM genotype for CYP2C19. Br J Clin Pharmacol. 2002;53(4):393\u20137. https:\/\/doi.org\/10.1046\/j.1365-2125.2002.01366.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1657_CR56","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1177\/0091270006287291","volume":"46","author":"BM Johnson","year":"2006","unstructured":"Johnson BM, Song IH, Adkison KK, Borland J, Fang L, Lou Y, et al. Evaluation of the drug interaction potential of Aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified Cooperstown 5 + 1 cocktail. J Clin Pharmacol. 2006;46(5):577\u201387. https:\/\/doi.org\/10.1177\/0091270006287291.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"1657_CR57","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s40261-013-0117-6","volume":"33","author":"G Chen","year":"2013","unstructured":"Chen G, Lee R, H\u00f8jer AM, Buchbjerg JK, Serenko M, Zhao Z. Pharmacokinetic drug interactions involving Vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig. 2013;33(10):727\u201336. https:\/\/doi.org\/10.1007\/s40261-013-0117-6.","journal-title":"Clin Drug Investig"},{"issue":"10","key":"1657_CR58","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1111\/j.1745-7254.2007.00617.x","volume":"28","author":"L Fan","year":"2007","unstructured":"Fan L, Wang G, Wang LS, Chen Y, Zhang W, Huang YF, et al. Herbal medicine Yin Zhi Huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of Omeprazole. Acta Pharmacol Sin. 2007;28(10):1685\u201392. https:\/\/doi.org\/10.1111\/j.1745-7254.2007.00617.x.","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"1657_CR59","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.clpt.2003.09.014","volume":"75","author":"LS Wang","year":"2004","unstructured":"Wang LS, Zhou G, Zhu B, Wu J, Wang JG, Abd El-Aty AM, et al. St John\u2019s Wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of Omeprazole. Clin Pharmacol Ther. 2004;75(3):191\u20137. https:\/\/doi.org\/10.1016\/j.clpt.2003.09.014.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1657_CR60","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1177\/0091270004263469","volume":"44","author":"M El Mouelhi","year":"2004","unstructured":"El Mouelhi M, Worley DJ, Kuzmak B, Destefano AJ, Thompson GA. Influence of Azimilide on CYP2C19-mediated metabolism. J Clin Pharmacol. 2004;44(4):373\u20138. https:\/\/doi.org\/10.1177\/0091270004263469.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1657_CR61","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/sj.clpt.6100187","volume":"82","author":"JY Ryu","year":"2007","unstructured":"Ryu JY, Song IS, Sunwoo YE, Shon JH, Liu KH, Cha IJ, et al. Development of the \u201cInje cocktail\u201d for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. Clin Pharmacol Ther. 2007;82(5):531\u201340. https:\/\/doi.org\/10.1038\/sj.clpt.6100187.","journal-title":"Clin Pharmacol Ther"},{"key":"1657_CR62","unstructured":"Alexion Pharmaceuticals Inc. AP. Drug Approval Package: VOYDEYA; Application Number: 218037. 2024. Report."},{"issue":"7","key":"1657_CR63","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1111\/bcp.15699","volume":"89","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Johnson M, Joshi S, Yazdani P, Zhan J, Wen B, et al. Open\u2010label, drug\u2013drug interaction study between the HIV\u20101 maturation inhibitor GSK3640254 and a metabolic probe cocktail in healthy participants. Br J Clin Pharmacol. 2023;89(7):2236\u201345. https:\/\/doi.org\/10.1111\/bcp.15699.","journal-title":"Br J Clin Pharmacol"},{"key":"1657_CR64","doi-asserted-by":"crossref","unstructured":"Catalano S, Grundman M, Schneider LS, DeKosky S, Morgan R, Guttendorf R, et al. P4-567: A Phase 1 safety trial of the A\u03b2 oligomer receptor antagonist CT1812. In: Alzheimer\u2019s Association International Conference. 2017.","DOI":"10.1016\/j.jalz.2017.07.730"},{"issue":"4","key":"1657_CR65","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/cts.13204","volume":"15","author":"SA Greene","year":"2022","unstructured":"Greene SA, Kwak C, Kamin M, Vernillet L, Glenn KJ, Gabriel L, et al. Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects. Clin Transl Sci. 2022;15(4):899\u2013911. https:\/\/doi.org\/10.1111\/cts.13204.","journal-title":"Clin Transl Sci"},{"key":"1657_CR66","unstructured":"Abbvie Inc. A Phase 1 Study to Evaluate the Effect of Multiple IV Infusions of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates Administered Orally in Subjects with Moderately to Severely Active Ulcerative Colitis or Crohn\u2019s Disease. M19-974 Clinical Study Report Synopsis R&D\/23\/0154. 2022. Report."},{"issue":"6","key":"1657_CR67","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.clpt.2005.02.010","volume":"77","author":"M Turpeinen","year":"2005","unstructured":"Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, Laine K. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2005;77(6):553\u20139. https:\/\/doi.org\/10.1016\/j.clpt.2005.02.010.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1657_CR68","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/00004714-199510000-00004","volume":"15","author":"TA Ketter","year":"1995","unstructured":"Ketter TA, Jenkins JB, Schroeder DH, Pazzaglia PJ, Marangell LB, George MS, et al. Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychopharmacol. 1995;15(5):327\u201333. https:\/\/doi.org\/10.1097\/00004714-199510000-00004.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"1657_CR69","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/sj.clpt.6100027","volume":"81","author":"GW Hogeland","year":"2007","unstructured":"Hogeland GW, Swindells S, McNabb JC, Kashuba ADM, Yee GC, Lindley CM. Lopinavir\/ritonavir reduces bupropion plasma concentrations in healthy subjects. Clin Pharmacol Ther. 2007;81(1):69\u201375. https:\/\/doi.org\/10.1038\/sj.clpt.6100027.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1657_CR70","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.clpt.2006.03.010","volume":"80","author":"KK Loboz","year":"2006","unstructured":"Loboz KK, Gross AS, Williams KM, Liauw WS, Day RO, Blievernicht JK, et al. Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther. 2006;80(1):75\u201384. https:\/\/doi.org\/10.1016\/j.clpt.2006.03.010.","journal-title":"Clin Pharmacol Ther"},{"key":"1657_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.649","author":"J de Jong","year":"2020","unstructured":"de Jong J, Mitselos A, Jurczak W, Cordoba R, Panizo C, Wrobel T, et al. Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6. Pharmacol Res Perspect. 2020. https:\/\/doi.org\/10.1002\/prp2.649.","journal-title":"Pharmacol Res Perspect"},{"issue":"4","key":"1657_CR72","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s40262-024-01352-9","volume":"63","author":"J Piscitelli","year":"2024","unstructured":"Piscitelli J, Reddy MB, Wollenberg L, Del Frari L, Gong J, Wood L, et al. Clinical evaluation of the effect of encorafenib on bupropion, rosuvastatin, and coproporphyrin I and considerations for statin coadministration. Clin Pharmacokinet. 2024;63(4):483\u201396. https:\/\/doi.org\/10.1007\/s40262-024-01352-9.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1657_CR73","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1365-2125.2010.03661.x","volume":"70","author":"H Kim","year":"2010","unstructured":"Kim H, Bae SK, Park S, Shim E, Kim H, Shon J, et al. Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4\u2010hydroxybupropion, in healthy subjects. Br J Clin Pharmacol. 2010;70(1):126\u201331. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03661.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1657_CR74","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/j.1365-2125.2012.04304.x","volume":"74","author":"W Qin","year":"2012","unstructured":"Qin W, Zhang W, Liu Z, Chen X, Tan Z, Hu D, et al. Rapid clinical induction of bupropion hydroxylation by metamizole in healthy Chinese men. Br J Clin Pharmacol. 2012;74(6):999\u20131004. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04304.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"1657_CR75","first-page":"1192","volume":"16","author":"LC Gao","year":"2012","unstructured":"Gao LC, Huang X, Tan ZR, Fan L, Zhou HH. The effects of sodium ferulate on the pharmacokinetics of bupropion and its active metabolite in healthy men. Eur Rev Med Pharmacol Sci. 2012;16(9):1192\u20136.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"5","key":"1657_CR76","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1128\/AAC.01600-07","volume":"52","author":"ED Kharasch","year":"2008","unstructured":"Kharasch ED, Mitchell D, Coles R, Blanco R. Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother. 2008;52(5):1663\u20139. https:\/\/doi.org\/10.1128\/AAC.01600-07.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1657_CR77","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1177\/0091270006286981","volume":"46","author":"LM Hesse","year":"2006","unstructured":"Hesse LM, Greenblatt DJ, von Moltke LL, Court MH. Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers. J Clin Pharmacol. 2006;46(5):567\u201376. https:\/\/doi.org\/10.1177\/0091270006286981.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1657_CR78","doi-asserted-by":"publisher","first-page":"e62489","DOI":"10.1371\/journal.pone.0062489","volume":"8","author":"L Gao","year":"2013","unstructured":"Gao L, He Y, Tang J, Yin J, Huang Z, Liu F, et al. Genetic variants of pregnane X receptor (PXR) and CYP2B6 affect the induction of bupropion hydroxylation by sodium ferulate. PLoS ONE. 2013;8(6):e62489\u2013e62489. https:\/\/doi.org\/10.1371\/journal.pone.0062489.","journal-title":"PLoS ONE"},{"issue":"11","key":"1657_CR79","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1177\/009127009903901111","volume":"39","author":"R Kustra","year":"1999","unstructured":"Kustra R, Corrigan B, Dunn J, Duncan B, Hsyu PH. Lack of effect of cimetidine on the pharmacokinetics of sustained-release bupropion. J Clin Pharmacol. 1999;39(11):1184\u20138.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1657_CR80","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/0091270007309709","volume":"48","author":"NA Farid","year":"2008","unstructured":"Farid NA, Payne CD, Ernest CS, Li YG, Winters KJ, Salazar DE, et al. Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans. J Clin Pharmacol. 2008;48(1):53\u20139. https:\/\/doi.org\/10.1177\/0091270007309709.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1657_CR81","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/cpdd.915","volume":"10","author":"I Landry","year":"2021","unstructured":"Landry I, Aluri J, Nakai K, Hall N, Miyajima Y, Ueno T, et al. Evaluation of the CYP3A and CYP2B6 drug-drug interaction potential of lemborexant. Clin Pharmacol Drug Dev. 2021;10(6):681\u201390. https:\/\/doi.org\/10.1002\/cpdd.915.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"12","key":"1657_CR82","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1002\/jcph.1689","volume":"60","author":"AR Polepally","year":"2020","unstructured":"Polepally AR, Ng JW, Salem AH, Dufek MB, Parikh A, Carter DC, et al. Assessment of clinical drug-drug interactions of elagolix, a gonadotropin-releasing hormone receptor antagonist. J Clin Pharmacol. 2020;60(12):1606\u201316. https:\/\/doi.org\/10.1002\/jcph.1689.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"1657_CR83","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/bcp.14508","volume":"87","author":"DB Pooler","year":"2021","unstructured":"Pooler DB, Ness DB, Sarantopoulos J, Squittieri N, Ravichandran S, Britten CD, et al. The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours. Br J Clin Pharmacol. 2021;87(3):1291\u2013302. https:\/\/doi.org\/10.1111\/bcp.14508.","journal-title":"Br J Clin Pharmacol"},{"key":"1657_CR84","unstructured":"Janssen Pharmaceuticals Inc. FDA Drug Approval Package: Spravato; Application Number: 211243. 2019. Report."},{"issue":"3","key":"1657_CR85","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/cpdd.844","volume":"10","author":"MEF Mohamed","year":"2021","unstructured":"Mohamed MEF, Minocha M, Trueman S, Feng T, Enejosa J, Fisniku O, et al. Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate. Clin Pharmacol Drug Dev. 2021;10(3):299\u2013306. https:\/\/doi.org\/10.1002\/cpdd.844.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1657_CR86","unstructured":"SK Life Science Inc. FDA Drug Approval Package: XCOPRI; Application Number: 212839. 2019. Report."},{"issue":"12","key":"1657_CR87","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1124\/dmd.109.029728","volume":"37","author":"JT Backman","year":"2009","unstructured":"Backman JT, Honkalammi J, Neuvonen M, Kurkinen KJ, Tornio A, Niemi M, et al. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe. Drug Metab Dispos. 2009;37(12):2359\u201366. https:\/\/doi.org\/10.1124\/dmd.109.029728.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"1657_CR88","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/clpt.2011.313","volume":"91","author":"J Honkalammi","year":"2012","unstructured":"Honkalammi J, Niemi M, Neuvonen PJ, Backman JT. Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses. Clin Pharmacol Ther. 2012;91(5):846\u201355. https:\/\/doi.org\/10.1038\/clpt.2011.313.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"1657_CR89","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1124\/dmd.111.040931","volume":"39","author":"J Honkalammi","year":"2011","unstructured":"Honkalammi J, Niemi M, Neuvonen PJ, Backman JT. Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses. Drug Metab Dispos. 2011;39(10):1977\u201386. https:\/\/doi.org\/10.1124\/dmd.111.040931.","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"1657_CR90","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1124\/dmd.116.070276","volume":"44","author":"SJ Kim","year":"2016","unstructured":"Kim SJ, Yoshikado T, Ieiri I, Maeda K, Kimura M, Irie S, et al. Clarification of the mechanism of Clopidogrel-mediated drug-drug interaction in a clinical cassette small-dose study and its prediction based on in vitro information. Drug Metab Dispos. 2016;44(10):1622\u201332. https:\/\/doi.org\/10.1124\/dmd.116.070276.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"1657_CR91","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.clpt.2005.11.002","volume":"79","author":"L Kajosaari","year":"2006","unstructured":"Kajosaari L, Niemi M, Backman J, Neuvonen P. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. Clin Pharmacol Ther. 2006;79(3):231\u201342. https:\/\/doi.org\/10.1016\/j.clpt.2005.11.002.","journal-title":"Clin Pharmacol Ther"},{"key":"1657_CR92","unstructured":"Epizyme Inc. Drug Approval Package: TAZVERIK, Application Number: 211723. 2020. Report."},{"issue":"3","key":"1657_CR93","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2165\/11599870-000000000-00000","volume":"32","author":"KA Schoedel","year":"2012","unstructured":"Schoedel KA, Pope LE, Sellers EM. Randomized open-label drug-drug interaction trial of Dextromethorphan\/Quinidine and paroxetine in healthy volunteers. Clin Drug Investig. 2012;32(3):157\u201369. https:\/\/doi.org\/10.2165\/11599870-000000000-00000.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"1657_CR94","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1177\/00912700022008702","volume":"40","author":"CL Alfaro","year":"2000","unstructured":"Alfaro CL, Lam YWF, Simpson J, Ereshefsky L. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: Intraindividual variability and plasma concentration correlations. J Clin Pharmacol. 2000;40(1):58\u201366. https:\/\/doi.org\/10.1177\/00912700022008702.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1657_CR95","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/jcpt.12042","volume":"38","author":"J Ju\u0159ica","year":"2013","unstructured":"Ju\u0159ica J, \u017dourkov\u00e1 A. Dynamics and persistence of CYP2D6 inhibition by paroxetine. J Clin Pharm Ther. 2013;38(4):294\u2013300. https:\/\/doi.org\/10.1111\/jcpt.12042.","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"1657_CR96","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/hup.598","volume":"19","author":"P Vandel","year":"2004","unstructured":"Vandel P, Haffen E, Nezelof S, Broly F, Kantelip JP, Sechter D. Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients. Hum Psychopharmacol Clin Exp. 2004;19(5):293\u20138. https:\/\/doi.org\/10.1002\/hup.598.","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"1657_CR97","unstructured":"Takeda Pharmaceuticals USA I. FDA Drug Approval Package: LIVTENCITY, Application Number: 215596. 2021. Report."},{"issue":"4","key":"1657_CR98","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1128\/AAC.50.4.1130-1135.2006","volume":"50","author":"JD Ma","year":"2006","unstructured":"Ma JD, Nafziger AN, Villano SA, Gaedigk A, Bertino JS. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother. 2006;50(4):1130\u20135. https:\/\/doi.org\/10.1128\/AAC.50.4.1130-1135.2006.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1657_CR99","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/jcph.1504","volume":"60","author":"IH Song","year":"2020","unstructured":"Song IH, Ilic K, Murphy J, Lasseter K, Martin P. Effects of Maribavir on P\u2010Glycoprotein and CYP2D6 in healthy volunteers. J Clin Pharmacol. 2020;60(1):96\u2013106. https:\/\/doi.org\/10.1002\/jcph.1504.","journal-title":"J Clin Pharmacol"},{"key":"1657_CR100","unstructured":"Takeda Pharmaceuticals USA I. LIVTENCITY. Prescribing Information. 2024."},{"issue":"10","key":"1657_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/metabo14100522","volume":"14","author":"J Yu","year":"2024","unstructured":"Yu J, Rioux N, Gardner I, Owens K, Ragueneau-Majlessi I. Metabolite measurement in index substrate drug interaction studies: A review of the literature and recent new drug application reviews. Metabolites. 2024;14(10):522. https:\/\/doi.org\/10.3390\/metabo14100522.","journal-title":"Metabolites"},{"issue":"9","key":"1657_CR102","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1002\/jcph.2447","volume":"64","author":"M Magliocca","year":"2024","unstructured":"Magliocca M, Berger B, Lemoine V, Kaufmann P, Dingemanse J. Value of assessing 1\u2010Hydroxymidazolam in drug\u2010drug interaction studies with midazolam as a substrate of cytochrome P450 3A. J Clin Pharmacol. 2024;64(9):1123\u20139. https:\/\/doi.org\/10.1002\/jcph.2447.","journal-title":"J Clin Pharmacol"},{"issue":"857","key":"1657_CR103","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jchromb.2007.07.007","volume":"1","author":"RKE Coles","year":"2007","unstructured":"Coles RKE. 17656162. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;1(857):67\u201375. https:\/\/doi.org\/10.1016\/j.jchromb.2007.07.007.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"6","key":"1657_CR104","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s11095-008-9535-1","volume":"25","author":"R Coles","year":"2008","unstructured":"Coles R, Kharasch ED. Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes. Pharm Res. 2008;25(6):1405\u201311. https:\/\/doi.org\/10.1007\/s11095-008-9535-1. (PubMed PMID: 18219560).","journal-title":"Pharm Res"},{"issue":"7","key":"1657_CR105","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1124\/dmd.104.003459","volume":"33","author":"S Borges","year":"2005","unstructured":"Borges S, Li L, Hamman MA, Jones DR, Hall SD, Gorski JC. Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance. Drug Metab Dispos. 2005;33(7):1052\u20135. https:\/\/doi.org\/10.1124\/dmd.104.003459.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"1657_CR106","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/00008571-199810000-00005","volume":"8","author":"AD Kashuba","year":"1998","unstructured":"Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Shirey CS, Gotschall R, et al. Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics. 1998;8(5):403\u201310. https:\/\/doi.org\/10.1097\/00008571-199810000-00005.","journal-title":"Pharmacogenetics"},{"issue":"7","key":"1657_CR107","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1177\/00912700122010627","volume":"41","author":"JS McCune","year":"2001","unstructured":"McCune JS, Lindley C, Decker JL, Williamson KM, Meadowcroft AM, Graff D, et al. Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan. J Clin Pharmacol. 2001;41(7):723\u201331. https:\/\/doi.org\/10.1177\/00912700122010627.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1657_CR108","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1365-2125.2006.02781.x","volume":"63","author":"NK Zgheib","year":"2007","unstructured":"Zgheib NK, Frye RF, Tracy TS, Romkes M, Branch RA. Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity. Br J Clin Pharmacol. 2007;63(4):477\u201387. https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02781.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1657_CR109","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2002.121216","volume":"71","author":"\u00dc Yasar","year":"2002","unstructured":"Yasar \u00dc, Forslund\u2010Bergengren C, Tybring G, Dorado P, LLerena A, Sj\u00f6qvist F, et al. Pharmacokinetics of losartan and its metabolite E\u20103174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther. 2002;71(1):89\u201398. https:\/\/doi.org\/10.1067\/mcp.2002.121216.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1657_CR110","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1046\/j.1365-2125.2002.01646.x","volume":"54","author":"U Yasar","year":"2002","unstructured":"Yasar U, Dahl ML, Christensen M, Eliasson E. Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity. Br J Clin Pharmacol. 2002;54(2):183\u20135. https:\/\/doi.org\/10.1046\/j.1365-2125.2002.01646.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1657_CR111","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/j.1365-2125.1991.tb05587.x","volume":"31","author":"MA Page","year":"1991","unstructured":"Page MA, Boutagy JS, Shenfield GM. A screening test for slow metabolisers of tolbutamide. Br J Clin Pharmacol. 1991;31(6):649\u201354. https:\/\/doi.org\/10.1111\/j.1365-2125.1991.tb05587.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1657_CR112","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/clpt.1990.46","volume":"47","author":"ME Veronese","year":"1990","unstructured":"Veronese ME, Miners JO, Randles D, Gregov D, Birkett DJ. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther. 1990;47(3):403\u201311. https:\/\/doi.org\/10.1038\/clpt.1990.46.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1657_CR113","doi-asserted-by":"publisher","first-page":"760","DOI":"10.2174\/138920012800840347","volume":"13","author":"EL Swart","year":"2012","unstructured":"Swart EL, Slort PR, Pl\u00f6tz FB. Growing up with midazolam in the neonatal and pediatric intensive care. Curr Drug Metab. 2012;13(6):760\u20136. https:\/\/doi.org\/10.2174\/138920012800840347.","journal-title":"Curr Drug Metab"},{"issue":"8","key":"1657_CR114","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/0006-2952(96)00501-1","volume":"52","author":"TS Tracy","year":"1996","unstructured":"Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR. Studies of flurbiprofen 4\u2019-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9. Biochem Pharmacol. 1996;52(8):1305\u20139. https:\/\/doi.org\/10.1016\/0006-2952(96)00501-1.","journal-title":"Biochem Pharmacol"},{"issue":"1\u20132","key":"1657_CR115","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.chroma.2008.10.122","volume":"1215","author":"A Petsalo","year":"2008","unstructured":"Petsalo A, Turpeinen M, Pelkonen O, Tolonen A. Analysis of nine drugs and their cytochrome P450-specific probe metabolites from urine by liquid chromatography\u2013tandem mass spectrometry utilizing sub 2\u03bcm particle size column. J Chromatogr A. 2008;1215(1\u20132):107\u201315. https:\/\/doi.org\/10.1016\/j.chroma.2008.10.122.","journal-title":"J Chromatogr A"},{"issue":"3","key":"1657_CR116","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/03602532.2019.1620763","volume":"51","author":"R Costa","year":"2019","unstructured":"Costa R, Oliveira NG, Dinis-Oliveira RJ. Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects. Drug Metab Rev. 2019;51(3):293\u2013313. https:\/\/doi.org\/10.1080\/03602532.2019.1620763.","journal-title":"Drug Metab Rev"},{"issue":"7","key":"1657_CR117","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1124\/dmd.112.045286","volume":"40","author":"C S\u00e4ll","year":"2012","unstructured":"S\u00e4ll C, Houston JB, Galetin A. A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance. Drug Metab Dispos. 2012;40(7):1279\u201389. https:\/\/doi.org\/10.1124\/dmd.112.045286.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1657_CR118","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1023\/a:1015835215945","volume":"6","author":"SJ Vetticaden","year":"1989","unstructured":"Vetticaden SJ, Cabana BE, Prasad VK, Purich ED, Jonkman JH, de Zeeuw R, et al. Phenotypic differences in dextromethorphan metabolism. Pharm Res. 1989;6(1):13\u20139. https:\/\/doi.org\/10.1023\/a:1015835215945.","journal-title":"Pharm Res"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01657-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01657-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01657-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:36:59Z","timestamp":1783748219000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01657-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":118,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1657"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01657-x","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T.D. wrote the manuscript; T.vI, K.M., and E.vH revised the manuscript; T.D. designed the research; T.vI, K.M., and E.vH. evaluated the proposed methodology and further supported method development; T.D. performed the research and analyzed the data; T.vI, K.M., and E.vH critically reviewed the results and interpretation of the analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"The authors declared no competing interests for this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets analyzed during the current study are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}}]}}